Ferreira Cesar Augusto, Vicente Walter Villela de Andrade, Evora Paulo Roberto Barbosa, Rodrigues Alfredo José, Klamt Jyrson Guilherme, Carlotti Ana Paula de Carvalho Panzeli, Carmona Fábio, Manso Paulo Henrique
Clinics Hospital, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Rev Bras Cir Cardiovasc. 2010 Jan-Mar;25(1):85-98. doi: 10.1590/s0102-76382010000100018.
To evaluate if the hemostatic high-dose aprotinin seems to reduce the inflammatory process after extracorporeal circulation (ECC) in children.
A prospective randomized study was conducted on children aged 30 days to 4 years submitted to correction of acyanogenic congenital heart disease with ECC and divided into two groups: Control (n=9) and Aprotinin (n=10). In the Aprotinin Group the drug was administered before and during ECC and the systemic inflammatory response and hemostatic and multiorgan dysfunctions were analyzed on the basis of clinical and biochemical markers. Differences were considered to be significant when P<0.05.
The groups were similar regarding demographic and intraoperative variables, except for a greater hemodilution in the Aprotinin Group. The drug had no benefit regarding time of mechanical pulmonary ventilation, permanence in the postoperative ICU and length of
In this series, hemostatic high-dose aprotinin did not minimize the clinical manifestations or serum markers of the inflammatory systemic response.
评估大剂量止血用抑肽酶是否似乎能减轻儿童体外循环（ECC）后的炎症反应。
对30天至4岁接受ECC纠正非紫绀型先天性心脏病的儿童进行了一项前瞻性随机研究，分为两组：对照组（n = 9）和抑肽酶组（n = 10）。在抑肽酶组中，在ECC前及ECC期间给予该药物，并根据临床和生化指标分析全身炎症反应以及止血和多器官功能障碍。当P<0.05时，差异被认为具有统计学意义。
除抑肽酶组有更大程度的血液稀释外，两组在人口统计学和术中变量方面相似。该药物在机械通气时间、术后重症监护病房停留时间和住院时间方面并无益处。
在本系列研究中，大剂量止血用抑肽酶并未使全身炎症反应的临床表现或血清标志物降至最低。
